Entera Bio Ltd.

Entera Bio Ltd. completed a private placement on July 28, 2026, raising approximately $275.0 million. The company issued an aggregate of 134,803,910 ordinary shares and pre-funded warrants to institutional and accredited investors, including funds affiliated with BVF Partners L.P., at a price of $2.04 per share. The net proceeds are intended to support the initiation of the company's phase 3 registrational study of EB613 in postmenopausal women with osteoporosis, as well as for general working capital and corporate purposes. BVF Partners L.P. also secured the right to designate two directors to Entera Bio's board.

Entera Bio Ltd. announced an oversubscribed private placement financing, expected to generate approximately $275 million in gross proceeds. The financing, led by BVF Partners L.P., is anticipated to extend the company's cash runway into 2030 and fully fund the Phase 3 registrational studies for EB613, its oral osteoporosis treatment. Additionally, the proceeds will advance EB612 into Phase 1 development and support general corporate purposes.

Entera Bio Ltd. shareholders approved a significant amendment to the company's Articles of Association, increasing the number of authorized Ordinary Shares from 140,010,000 to 350,000,000. Additionally, shareholders approved an increase of 2,500,000 Ordinary Shares to the 2018 Equity Incentive Plan. The Annual Meeting also saw the election of three Class III directors and the approval of various compensation-related proposals for directors and the CEO.

Entera Bio Ltd. reported positive preclinical data for its EB612 and EB618 pipeline programs at ENDO 2026. EB612, an oral peptide for hypoparathyroidism, demonstrated robust bioavailability and sustained calcium increases across three preclinical models, with an Investigational New Drug (IND) application expected in late 2026. EB618, an oral dual GLP-1/glucagon receptor agonist for obesity, showed dose-proportional pharmacokinetics and a strong effect on blood glucose in non-human primates. Both programs are co-developed with OPKO Health Inc.

Entera Bio Ltd. reported positive comparative Phase 1 data for its oral osteoporosis treatment, EB613, at ENDO 2026. The single-tablet formulation of EB613 demonstrated a pharmacokinetic (PK) and pharmacodynamic (PD) profile comparable to both the multi-tablet version and Forteo® (teriparatide SC injection). This significant scientific achievement supports the advancement of single-tablet EB613 into Entera's planned Phase 3 study for postmenopausal women with osteoporosis, offering a potential oral anabolic treatment alternative to daily injections.

Entera Bio Ltd. has filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders, scheduled for July 14, 2026. Key agenda items include the election of three Class III directors, approval of amended compensation terms for non-executive directors, and share-based compensation for specific directors and the CEO. Shareholders will also vote on amendments to the 2018 Equity Incentive Plan and the company's Articles of Association to increase authorized share capital. The appointment of Kesselman & Kesselman (PwC) as independent auditors for fiscal year 2026 is also on the agenda.

Entera Bio Ltd. announced that new clinical data supporting its single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation at ENDO 2026. Additionally, abstracts for pre-clinical results of EB612 for hypoparathyroidism and PK-PD study results for EB618 for obesity and metabolic disorders were also accepted for presentation at the annual meeting. The company is a clinical-stage firm focused on oral peptide and protein replacement therapies.

Entera Bio Ltd. reported a net loss of $3.5 million for the first quarter of 2026, an increase from $2.6 million in the prior year. The company's cash and cash equivalents decreased to $4.1 million by March 31, 2026, and management noted substantial doubt about its ability to continue as a going concern. However, in April 2026, Entera Bio completed a private placement, raising approximately $10.0 million to support its operations and the planned Phase 3 study for EB613. Additionally, the collaboration agreement with OPKO was expanded to include the development of EB612 for hypoparathyroidism.

Entera Bio Ltd. reported a net loss of $3.5 million for the first quarter of 2026, an increase from $2.6 million in Q1 2025, with R&D expenses also rising. The company provided significant business updates, including the submission of a streamlined Phase 3 protocol for its oral osteoporosis treatment, EB613, to the FDA. Additionally, Entera expanded its 50/50 partnership with OPKO for EB612, an oral hypoparathyroidism treatment, with an IND filing expected in late 2026. A direct investment led by BVF Partners L.P. brought the company's cash and cash equivalents to $20.4 million as of May 8, 2026, expected to fund operations through Q1 2027.

Entera Bio Ltd. reported its first-quarter 2026 financial results, including a net loss of $3.5 million, and provided key business updates. The company secured a direct investment led by BVF Partners L.P., raising $8.5 million, bringing total cash to $20.4 million as of May 8, 2026, expected to fund operations through Q1 2027. Significant pipeline advancements include the submission of the EB613 Phase 3 protocol to the FDA for osteoporosis and an expanded 50/50 partnership with OPKO for EB612, with an IND filing planned for late 2026. The company also announced management changes, appointing Geno J. Germano as Chairman.